Literature DB >> 1954384

Duration of the preclinical phase of chronic myelogenous leukemia: a case report.

E Berman1, A Strife, D Wisniewski, S Desai, S Gulati, S Jhanwar, B D Clarkson.   

Abstract

The molecular events that allow for clonal expansion of the malignant population in chronic myelogenous leukemia (CML) are poorly understood. Recent experiments in transgenic mice suggest a close temporal relationship between expression of the aberrant protein and manifestation of a hematologic neoplasm that resembles CML; tracing the same phenomenon in humans has not been possible. We studied a patient who underwent autologous bone marrow harvest after completion of chemotherapy and radiation therapy for advanced stage Hodgkin's disease. At the time of harvest his peripheral blood counts and bone marrow were morphologically normal. Sixteen months later he developed the clinical manifestations of CML. Detailed molecular evaluation of the harvested marrow showed that a small number of cells contained the Philadelphia chromosome. The time interval required for expansion of the malignant clone, as suggested by this particular patient, was at least 16 months although it is recognized that this figure may be variable.

Entities:  

Mesh:

Year:  1991        PMID: 1954384

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  Systematic review of pre-clinical chronic myeloid leukaemia.

Authors:  Jew Win Kuan; Anselm Ting Su; Chooi Fun Leong; Motomi Osato; Goro Sashida
Journal:  Int J Hematol       Date:  2018-09-14       Impact factor: 2.490

2.  Secondary chronic myelogenous leukemia after autologous peripheral blood stem cell transplantation for lymphoma.

Authors:  H H Hsiao; T C Liu; C S Chang; Y C Sue; T P Chen; S F Lin
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

3.  A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma.

Authors:  Hyunji Choi; Sung Ran Cho; Dahae Yang; Woonhyoung Lee; Hyunyong Hwang; Ho Sup Lee; Da Jung Kim; Taeyun Kim; Mi Hyang Kim
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.